Experienced in Chronic Obstructive Pulmonary Disease (COPD)

Joachim Quernheim-Muller

Freiburg, BW, DE 
Experienced in Chronic Obstructive Pulmonary Disease (COPD)
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Joachim Quernheim-Muller practices in Freiburg, Germany. Mr. Quernheim-Muller is rated as an Experienced expert by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Sarcoidosis, Beryllium Disease, Acute Interstitial Pneumonia, Lung Transplant, and Endoscopy.

His clinical research consists of co-authoring 107 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Chronic Obstructive Pulmonary Disease (COPD).

Gender
Male

Locations

Freiburg, BW 79106, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
View 1 Less Clinical Trial

107 Total Publications

Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy-Shedding of ACE2 and TMPRSS2 via ADAM10.
Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy-Shedding of ACE2 and TMPRSS2 via ADAM10.
Journal: International journal of molecular sciences
Published: February 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Quernheim-Muller's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile